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RESEARCH ARTICLE

Next-Generation Sequencing of Minimal
Residual Disease for Predicting Relapse
after Tisagenlecleucel in Children and Young
Adults with Acute Lymphoblastic Leukemia
Michael A. Pulsipher1, Xia Han2, Shannon L. Maude3,4, Theodore W. Laetsch3,4,5, Muna Qayed6,7,
Susana Rives8, Michael W. Boyer9, Hidefumi Hiramatsu10, Gregory A. Yanik11, Tim Driscoll12,
G. Doug Myers13, Peter Bader14, Andre Baruchel15,16, Jochen Buechner17, Heather E. Stefanski18,
Creton Kalfoglou2, Kevin Nguyen2, Edward R. Waldron2, Karen Thudium Mueller2, Harald J. Maier19,
Gabor Kari19, and Stephan A. Grupp3,4

Illustrated by Katie Vicari

We assessed minimal residual disease (MRD) detection and B-cell aplasia after tisagenlecleucel therapy for acute lymphoblastic leukemia (ALL) to define biomarkers
predictive of relapse (N = 143). Next-generation sequencing (NGS) MRD detection >0 in bone marrow
(BM) was highly associated with relapse. B-cell recovery [signifying loss of functional chimeric antigen
receptor (CAR) T cells] within the first year of treatment was associated with a hazard ratio (HR) for
relapse of 4.5 [95% confidence interval (CI), 2.03–9.97; P < 0.001]. Multivariate analysis at day 28 showed
independent associations of BMNGS-MRD >0 (HR = 4.87; 95% CI, 2.18–10.8; P < 0.001) and B-cell recovery (HR = 3.33; 95% CI, 1.44–7.69; P = 0.005) with relapse. By 3 months, the BMNGS-MRD HR increased
to 12 (95% CI, 2.87–50; P < 0.001), whereas B-cell recovery was not independently predictive (HR = 1.27;
95% CI, 0.33–4.79; P = 0.7). Relapses occurring with persistence of B-cell aplasia were largely CD19−
(23/25: 88%). Detectable BMNGS-MRD reliably predicts risk with sufficient time to consider approaches
to relapse prevention such as hematopoietic cell transplantation (HCT) or second CAR-T cell infusion.

ABSTRACT

SIGNIFICANCE: Detectable disease by BMNGS-MRD with or without B-cell aplasia is highly predictive
of relapse after tisagenlecleucel therapy for ALL. Clonotypic rearrangements used to follow NGS-MRD
did not change after loss of CD19 or lineage switch. High-risk patients identified by these biomarkers
may benefit from HCT or investigational cell therapies.
See related commentary by Ghorashian and Bartram, p. 2.

INTRODUCTION
Treatment with tisagenlecleucel has led to long-term remission in up to 50% of children and young adults with relapsed
or refractory acute lymphoblastic leukemia (ALL) who were
previously rarely curable (1). This autologous, targeted
immunocellular therapy has also led to a paradigm shift in
therapeutic choices: Prior to availability of tisagenlecleucel,
curative approaches to multiply relapsed/refractory ALL
ended in treatment with allogeneic hematopoietic cell transplantation (HCT) in the fraction of patients who were able
to achieve good remission and qualify for transplant (2).
Following tisagenlecleucel treatment, however, there is a percentage of patients who have long-term remissions without
further therapy, the longest of which has exceeded 9 years (3).
1
Section of Transplantation and Cellular Therapy, Children’s Hospital Los
Angeles Cancer and Blood Disease Institute, USC Keck School of Medicine,
Los Angeles, California. 2Novartis Pharmaceuticals Corporation, East
Hanover, New Jersey. 3Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 4Division of
Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania. 5Department of Pediatrics, The University of Texas Southwestern
Medical Center, Dallas, Texas. 6Department of Pediatrics, Emory University
School of Medicine, Atlanta, Georgia. 7Aflac Cancer and Blood Disorders
Center, Healthcare of Atlanta, Atlanta, Georgia. 8Pediatric Hematology,
Hospital Sant Joan de Déu de Barcelona, Fundació Sant Joan de Déu, Barcelona, Spain. 9Department of Pediatrics and Internal Medicine, University
of Utah, Salt Lake City, Utah. 10Department of Pediatrics, Graduate School
of Medicine, Kyoto University, Kyoto City, Japan. 11Michigan Medicine Bone
Marrow Transplant and Leukemia, C.S. Mott Children’s Hospital, Ann Arbor,
Michigan. 12Pediatric Blood and Marrow Transplant, Duke University Medical Center, Durham, North Carolina. 13Pediatric Hematology and Oncology,
Children’s Mercy Hospital; University of Missouri—Kansas City School
of Medicine, Kansas City, Missouri. 14Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine Hospital for Children and
Adolescents University Hospital Frankfurt, Frankfurt, Germany. 15Pediatric Hemato-Immunology Department, Hôpital Universitaire Robert Debré

Second-generation chimeric antigen receptor (CAR) T cell
therapies using 4-1BB costimulation have led to minimal
residual disease (MRD)–negative remissions by multiparameter flow cytometry (MFC) in approximately 80% to 97% of
patients treated (1, 4–6). Although high percentages achieve
remission, a portion of patients will lose their CAR T cells
within a few months. B-cell aplasia is a marker of functional
CD19 CAR persistence, so B-cell recovery/loss of B-cell aplasia suggests loss of functional CAR-T cells. Other patients
will relapse in spite of CAR-T persistence as a result of CD19
escape, either from mutated CD19 splice variants that are
no longer recognized by tisagenlecleucel, genetic mutations
in CD19 that lead to truncated proteins with loss of surface
antigen, or lineage switch in blasts with loss of CD19 (7, 8).
With these issues in mind, a challenge in managing patients
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with ALL CAR-T is that there are not reliable markers to predict relapse. This has led some to propose allogeneic HCT for
all patients early after CAR-T cell therapy to minimize relapse
risk (9, 10)
MRD is currently used for risk stratification of patients
with ALL receiving chemotherapy and HCT (11, 12). The
Children’s Oncology Group has a standardized MFC assay
that detects disease reliably in marrow or peripheral blood at
levels ≥0.01% of mononuclear cells (11). More sensitive MRD
assays use detection of specific immunoglobulin (Ig)H or
T-cell receptor rearrangements, either by allele-specific polymerase chain reaction (PCR) or by next-generation sequencing (NGS). The NGS-MRD approach has been shown to
reliably detect blasts at levels ≤10−6 cells (13). Using this
approach, children with ALL at very low risk of relapse after
chemotherapy or HCT can be identified (14, 15). Published
data of NGS-MRD in CAR-T cell therapy for ALL are limited to a single study: The Fred Hutchinson group showed
improved event-free survival (EFS) with NGS negativity at a
single time point (D21) after infusion of CAR-T cells in 28
adult patients (16). The prognostic value of NGS-MRD has
not been demonstrated in pediatric and young adult patients
treated with tisagenlecleucel, or with assessments over time.
On the basis of our hypothesis that MRD measurements
at various time points after achieving remission with tisagenlecleucel could identify patients at high or low risk of
relapse after CAR-T cell therapy, we analyzed blood and
marrow samples from patients enrolled in the ELIANA and
ENSIGN trials and compared MFC-MRD with NGS-MRD.
We also looked at the influence of the presence or absence of
B-cell aplasia and its effect on predictive models for patient
outcome. Finally, we compared several distinct patterns separating CD19− relapse from CD19+ relapse.

RESULTS
Population and MRD Sampling
A total of 1,771 MFC samples were analyzed from 143
patients enrolled in the ENSIGN and ELIANA studies
(median follow-up 38.4 months). A total of 474 samples from
109 patients were analyzed for NGS-MRD. A total of 426
(90%) passed quality control, including 125 blood and 301
bone marrow (BM) samples. Time points were from screening
to 24 months after infusion, with 79% of postinfusion samples drawn at 1, 3, and 6 months (Supplementary Table S1A
and S1B). The MFC analysis was a scheduled part of the trials
and performed centrally on fresh samples, whereas the NGSMRD analysis was post hoc and performed on frozen samples
from the same blood and marrow draws. Ninety-five percent
of baseline blast samples allowed identification of a tumor
clone by NGS-MRD. A total of 387 samples were informative
for both MFC and NGS-MRD.
There are no significant differences between the subgroup
of patients with NGS-MRD samples available compared with
those without (Table 1) except for a trend toward fewer
patients with prior HCT in the non-NGS group. Notably, the
patients undergoing this analysis were a very high-risk population, with 58% relapsed after a previous allogeneic HCT and
69% with high marrow tumor burden (blast count and/or
flow MRD ≥50%) at enrollment.
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Sensitivity of MFC-MRD and NGS-MRD in BM
and Blood
To define the relative sensitivity of ALL blast detection
in blood and marrow by MFC-MRD and NGS-MRD sampling, we compared the results of the different methods
in the same samples. As expected, MFC-MRD detected a
higher percentage of blasts in BM compared with peripheral blood (Fig. 1A). This was also true in NGS samples,
wherein BMNGS-MRD detection was approximately one
log higher (Fig. 1B). BMNGS-MRD resulted in comparable detection to BMMFC-MRD at levels above 10−4, but as
expected, NGS-MRD was much more sensitive, showing high
numbers of samples that were NGS-MRD positive (MRD+)
but MFC-MRD negative (MRD−; Fig. 1C). In a further comparison of peripheral blood NGS-MRD with BMMFC-MRD,
we noted that peripheral blood NGS-MRD was more sensitive at detecting disease (Fig. 1D): 9% (7/77) more samples
were detected by peripheral blood NGS-MRD at a sensitivity
level of 10−6 than those detected by BMMFC-MRD, with 13%
(10/77) more detected if any level of detection was allowed
compared with MFC-MRD of marrow. This means that 10
patients had detectable peripheral blood NGS-MRD but
negative BMMFC-MRD, which was clinically meaningful
as 5 developed BM/extramedullary relapse, 4 received HCT/
additional therapy, and 1 was lost to follow-up.
Figure 1E and F give insight into the concordance of
MFC-MRD with NGS-MRD and the increased sensitivity of
NGS-MRD. MFC-MRD limit of sensitivity is 10−4, whereas
NGS-MRD provides reliable sensitivity of ≥10−6. NGS-MRD
can be reported with sensitivity cutoffs that vary depending
on the level of sensitivity desired and the cell numbers provided. The 151 baseline and postinfusion samples detected
as positive by MFC assessment aligned well with NGS-MRD
results (Pearson r of 0.81). In addition, for 287 postinfusion
samples (from 95 patients) with both NGS and MFC results
available, MFC detected 18% (51/287) as MRD+, whereas NGS
detected 22% (62/287), 29% (82/287), 33% (96/287), and 41%
(118/287) as MRD+ at sensitivity cutoff levels of 10−4, 10−5,
10−6, and any detectable level (which may roughly correspond
to 10−7), respectively. There were 88% more samples detected
by NGS than those detected by MFC (96 vs. 51) if a sensitivity level of 10−6 was used, and 131% more detected (118 vs.
51) when including samples with any detectable disease.
Notably, there were no samples that were MFC-MRD+ and
NGS-MRD−.
Data shown in Fig. 1E and F demonstrate that that there
are many cases for which disease was detected by NGS-MRD
and not by flow, with the corresponding data points visible
close to the y-axis. Notably, a detection sensitivity cutoff of
10−6 excludes many positive samples below this level. To distinguish sample groups including any level of detectable disease from higher cutoff levels such as 10−4 or 10−6, they were
designated as NGS-MRD >0, whereas samples negative for
any detectable disease were designated as NGS-MRD = 0. One
patient had a relapsed sample with 28% MRD in blood by
NGS but not detected by BMMFC. This patient experienced
a morphologic relapse with no B-cell markers, consistent with
lineage switch [had previously had a mixed-lineage leukemia
(MLL) rearrangement], and the relapse was missed by MFC.
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Table 1. Baseline patient characteristics in the NGS and non-NGS cohorts
NGS population (n = 109)

Non-NGS population (n = 34)

P

Overall population (N = 143)

Age, years, n (%)
<10
≥10 to <18
≥18
Median (min, max)

39 (35.8)
48 (44.0)
22 (20.2)
12 (3, 25)

13 (38.2)
19 (55.9)
2 (5.9)
12 (4, 18)

0.128

52 (36.4)
67 (46.9)
24 (16.8)
12 (3, 25)

Sex, n (%)
Female
Male

51 (46.8)
58 (53.2)

17 (50.0)
17 (50.0)

0.845

68 (47.6)
75 (52.4)

Race, n (%)
Asian
Other
White

11 (10.1)
14 (12.8)
84 (77.1)

4 (11.8)
4 (11.8)
26 (76.5)

0.943

15 (10.5)
18 (12.6)
110 (76.9)

3 (1, 9)

3 (1, 6)

Number of previous lines of
therapy, median (min, max)

3 (1, 9)

Complex karyotypes (≥5 abnormal), n (%)
No
75 (68.8)
Yes
34 (31.2)

23 (67.6)
11 (32.4)

1

98 (68.5)
45 (31.5)

Down syndrome
No
Yes

101 (92.7)
8 (7.3)

32 (94.1)
2 (5.9)

1

133 (93.0)
10 (7.0)

Refractory/relapse status at study entry, n (%)
Primary refractory
8 (7.3)
Relapsed disease
101 (92.7)

5 (14.7)
29 (85.3)

0.191

13 (9.1)
130 (90.9)

Prior HCT, n (%)
No
Yes

46 (42.2)
63 (57.8)

21 (61.8)
13 (38.2)

0.051

67 (46.9)
76 (53.1)

Enrollment BM tumor burden, n (%)
High
Low

75 (68.8)
34 (31.2)

23 (67.6)
11 (32.4)

1

98 (68.5)
45 (31.5)

103 (94.5)
4 (3.7)
2 (1.8)

31 (91.2)
3 (8.8)
0 (0)

0.393

LD chemotherapy group, n (%)
Fludarabine based
No LD chemotherapy
Non–fludarabine based

134 (93.7)
7 (4.9)
2 (1.4)

NOTE: P values comparing subgroup differences between NGS and non-NGS populations are from Fisher exact test.
Abbreviation: LD, lymphodepleting.

MRD Detection and Time to Relapse in the Context
of NGS-MRD Detection Quality and Quantitation
NGS-MRD assays can be reported out at specific cutoff
levels to ensure a high level of confidence that a threshold
level of disease is present. To reach that level of confidence,
a reasonable number of cells and a specific quality of DNA
need to be included. As we analyzed our NGS-MRD data, we
noted that a number of patients had detectable disease, but
because values did not reach thresholds required for the limit
of detection (LOD) or limit of quantitation (LOQ), they were
not reported out as positive for the 10−6 cutoff (Fig. 2A, left).
The right panel of Fig. 2A illustrates that the LOD and LOQ
can vary several logs. For samples with high blast counts, this
is not an issue, and definitive values can be reported, but at

these very low disease levels, the percentage of samples with
disease detected that fall below LOD or LOQ increases. To
investigate the clinical relevance of samples with <LOD/LOQ
MRD levels, we analyzed outcomes of 19 responding patients
with NGS-MRD+ disease below the 10−6 cutoff. Fourteen of
them relapsed or became MFC-MRD+, four were censored for
additional therapy, and only one had an ongoing remission
(Supplementary Fig. S1).
To assess the lead time different MRD approaches give
prior to relapse, we compared the time between the first
observation of MFC-MRD, NGS-MRD at a sensitivity of
10−6, and NGS-MRD detectable below the 10−6 cutoff in
patients who eventually relapsed (Fig. 2B). With the sampling schedule associated with this protocol (BM at 1, 3, 6, 9,
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Figure 1. Comparisons of the sensitivity of MFC-MRD and NGS-MRD from peripheral blood and BM. Vertical and horizonal dotted lines represent the

sensitivity cutoff for MFC and NGS, respectively. A, MFC-MRD from blood (y-axis) compared with samples from the same time point obtained from BM
(x-axis); n = 450. B, NGS-MRD from blood (y-axis) compared with samples from the same time point obtained from BM (x-axis); n = 66. C, NGS-MRD from
BM (y-axis) compared with MFC-MRD from BM (x-axis) in all matched samples; n = 280. D, NGS-MRD from blood (y-axis) compared with MFC-MRD from
BM (x-axis) in all matched samples; n = 77. E, NGS-MRD compared with MFC-MRD in all matched samples with an NGS sensitivity cutoff of 10−4. F, NGS-MRD
compared with MFC-MRD in all matched samples with an NGS sensitivity cutoff of 10−6. E and F, Green, red, blue, and purple dots represent baseline
index clones, NGS-MRD−, NGS-MRD+, and NGS-MRD indeterminate (insufficient number of cells to determine MRD), respectively.

and 12 months), relapse was noted without previous MRD
detection in 50% of patients by MFC, 31% of patients by
NGS-MRD at a sensitivity of 10−6, and 0% of patients with
NGS-MRD detectable below the 10−6 level. For those whose
MRD was detected prior to overt relapse, the median time
to relapse was 52 (range, 14–86) days from first MFC-MRD
detection, 70 (range, 15–196) days from NGS-MRD detected
above 10−6, and 168 (range, 47–330) days from detection in
patients with detectable NGS-MRD below the 10−6 cutoff.
This shows that the more sensitive NGS measurements
detect disease at levels that offer sufficient lead time prior to
overt relapse to allow repeat sampling and/or coordination
of therapeutic interventions.

Predictive Power of BMMFC-MRD and
BMNGS-MRD
Patients who achieved complete remission (CR)/CR with
incomplete hematologic recovery (CRi) but did not achieve
BMMFC-negative remission at day 28 and/or month 3
70 | BLOOD CANCER DISCOVERY
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after tisagenlecleucel infusion did poorly. Of 109 day 28 CR
patients, 2 were BM MRD+ by MFC. These patients relapsed
on day 80 and day 85, and died without additional therapy.
There were 5 of 82 patients who achieved CR/CRi by 3 months
and were BMMFC-MRD+. Two went on to relapse at day 92
and day 106, one underwent HCT (day 93), one received other
therapy at day 151, and one was lost to follow-up at day 86.
For patients who were able to achieve CR/CRi, we hypothesized that measures of BMNGS-MRD and B-cell aplasia at
key time points after tisagenlecleucel infusion would allow us
to more accurately predict risk of relapse and overall survival
(OS). We started by analyzing BMNGS-MRD+ patients who
were considered positive at a cutoff of 10−6 versus all patients
with measurements that did not meet this cutoff (BMNGSMRD >0; Fig. 3A and B). Surprisingly, the EFS and OS for
these two groups were not significantly different (P = 0.53
and P = 0.46, respectively). We noted that there were 10 NGSMRD+ measurements with a sensitivity cutoff of 10−6 in this
cohort, but there were another 10 patients with NGS-MRD >0
AACRJournals.org
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Figure 2. Characteristics of NGS-reported MRD values and their associated lead times ahead of clinical relapse. A, Characteristics of reported values

for BMNGS-MRD; x-axis represents individual samples, and y-axis represents a quantitative measure of MRD (normalized number of malignant cells in
1 million nucleated cells). For each sample, there is an LOD (shown by an orange circle) and an LOQ (shown by a purple ×). These quantities are directly
proportional to the number of cells provided to the assay; samples with higher numbers of input cells allow more reliable detection and quantitation of
residual disease at low levels. Positive test values below the LOD suggest that although residual disease is likely present, it might not be observed again
if a repeat test of the same sample source (blood or marrow) were sent. Positive test values below the LOQ imply that the reported MRD frequencies may
be inaccurate, although such values may be of the correct order of magnitude. The left panel shows samples that were detectable but below the LOD and
LOQ, whereas the right panel shows samples that were considered positive (above LOD and LOQ) at the cutoff level of 10−6. B, Cumulative frequencies to
overt relapse after patients achieved MFC-MRD+ (blue line), NGS-MRD+ at 10−6 level (green), and NGS-MRD+ below the 10−6 level but still detectable (red)
were plotted using the Kaplan–Meier method.
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Figure 3. CR/CRi patients with detectable BMNGS-MRD at the end of day 28, month 3, and month 6 after tisagenlecleucel therapy had significantly

shorter EFS and OS by Kaplan–Meier analyses, with the log-rank test P values included. EFS (A) and OS (B) of responding patients with BMNGS-MRD−
based on cutoff of 10−6 at day 28 (green line) versus those with BMNGS-MRD+ (blue lines). EFS (C) and OS (D) of responding patients based on detection
of BMNGS-MRD at 28 days at any level (blue lines) compared with patients with BMNGS-MRD = 0 (green lines). EFS (E) and OS (F) of responding patients
based on detection of NGS-MRD at 3 months at any level (blue lines) compared with patients with BMNGS-MRD = 0 (green lines). EFS (G) and OS (H) of
responding patients based on detection of BMNGS-MRD at 6 months at any level (blue lines) compared with patients with BMNGS-MRD = 0 (green lines).
CI, confidence interval; NE, not estimable.

72 | BLOOD CANCER DISCOVERY

JANUARY 2022

AACRJournals.org

NGS-MRD and Relapse Risk after Tisagenlecleucel for ALL

at day 28 (Fig. 1F). To assess the impact of increased sensitivity of our NGS-MRD testing, we analyzed the dataset with a
comparison of NGS-MRD = 0 versus NGS-MRD >0, which
included any level of detection (Fig. 3C and D). This led to
a dramatic improvement in our ability to determine populations at higher and lower risk of relapse (NGS-MRD = 0 EFS
of 68% [95% confidence interval (CI), 54–86] at 2 years versus
23% (95% CI, 8.8–62) for NGS-MRD >0 (P = 0.00047). Lower
relapse rate led to much higher OS in this cohort [2-year OS
with NGS-MRD = 0 of 84% (95% CI, 74–96) vs. 47% (95% CI,
29–77) for NGS MRD >0; P = 0.0038].
The lower curve of Fig. 3C suggests that a small percentage of patients with BMNGS-MRD+ disease at day 28
may have longer term remissions. To analyze this in more
detail, we looked at patients who were BMNGS-MRD >0
who either stayed positive or who became negative at later
time points. The prognosis of patients with consecutive
BMNGS-MRD >0 tests was uniformly poor. Of 26 patients
with consecutive BMNGS-MRD >0 tests, 19 relapsed, 6 were
censored for HCT or other new cancer therapies because
of B-cell recovery and/or BMMFC-MRD+, and 1 was lost
to follow-up. Prognosis of those with a BMNGS-MRD >0
test followed by subsequent BMNGS-MRD = 0 results was
mixed. Of four patients with BMNGS-MRD >0 at day 28
who turned MRD = 0 at month 3 and remained 0 at later
time points, two had ongoing CR (>40 months), one had
a late CD19− relapse at day 1,057, and one had HCT at
day 140 for the indication of early B-cell recovery. CAR
transgene levels in the blood in these four patients were well
above detectable levels (>1,500 copies/μg gDNA) at day 28.
Of three patients with BMNGS-MRD >0 at day 28, NGSMRD = 0 at month 3, and BMNGS-MRD >0 at month 6,
two relapsed and one was censored for HCT. These three
patients had low or minimal blood CAR transgene levels
by month 6 (two undetectable, and one with 40 copies/μg
gDNA). In summary, although patients with two BMNGS
MRD >0 values had extremely poor outcomes, a positive
test followed by sequential negative tests could sometimes
identify long-term survivors without further therapy.
At 3 and 6 months after infusion, a similar predictive
power for less relapse and better OS could be shown for
patients with BMNGS-MRD = 0 (Fig. 3E–H). Notably, at 3
and 6 months, those with any detectable NGS-MRD disease
had a dismal outcome. Of 14 with NGS-MRD >0 at month
3, 9 relapsed between month 4 and month 10 (all dying by
month 15), 3 went to HCT (all alive) and 2 received additional
cancer therapy (1 relapsed shortly thereafter and died, and 1
remained alive at last follow-up). Of 13 with NGS-MRD >0 at
month 6, 9 relapsed between month 7 and month 15, 1 went
to HCT and remains alive at last follow-up, and 3 went on to
have additional cancer therapy (2 alive and 1 lost to followup). No one with NGS-MRD >0 detected at these later time
points survived without significant additional intervention.
At 3 and 6 months, using positive BMNGS-MRD with a cutoff of 10−6 was predictive of poor outcome (Supplementary
Fig. S2A–S2D), but the best predictor at all time points was
using a cutoff of NGS-MRD >0.
To determine the specificity of very low levels of NGS-MRD,
we analyzed the MRD-defining sequences of 22 samples from
19 patients with MRD detected below LOD/LOQ 10−6 cutoffs
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compared with the Adaptive “uniqueness” database. All 21 of
the unique sequences from this cohort (17 IgH VDJ, 1 IgH DJ,
2 IgK, and 1 IgL) fell into the “most unique” category, with
probability scores ranging from 7.5 × 10−8 to 2.4 × 10−41. To
calculate the specific risk of false positives in our cohort, we
assessed whether the MRD-defining sequences of these 19
patients were detected at any level in the 316 MRD samples
run for this study. The false-positive rate was calculated as the
total number of matches in the nonmatched patients’ repertoires divided by the total number of comparisons against
nonmatched patients’ repertoires [23/6,863; 3.4 × 10−3 (95%
CI, 2.2 × 10−3 to 4.9 × 10−3)]. While a rate of less than 1% is
reassuring, being less than 1%, because multiple sequences
are tracked for each patient, the probability of a false positive
with these sequences is much lower.

Predictive Power of the Loss of B-cell Aplasia
We performed Kaplan–Meier analyses of EFS in patients
with continued B-cell aplasia versus those who recovered B
cells between 1 to 3 months, 3 to 6 months, 6 to 9 months,
and 9 to 12 months after tisagenlecleucel infusion. The
analysis showed statistically worse outcomes of patients losing B-cell aplasia prior to month 9 (Supplementary Fig. S3A–
S3D). Notably, only three patients lost B-cell aplasia between
6 to 9 months and two patients between 9 to 12 months.
To quantitate this effect, we built a Cox model for EFS with
B-cell recovery as a time-dependent covariate to assess the
risk of relapse after a patient had B-cell recovery. As shown
in Fig. 4, patients who had B-cell recovery during the first
year had significantly higher risk of relapse compared with
those without B-cell recovery [hazard ratio (HR) = 4.5; 95%
CI, 2.03–9.97; P < 0.001; Fig. 4A], with predicted EFS at
2 years of 9% and 14% for those with B-cell recovery at 3
and 6 months, respectively (Fig. 4B). Notably, there is steady
improvement in EFS for patients who arrive at 3 through 12
months with persistent B-cell aplasia [Fig. 4C; 2-year EFS values for persistence of B-cell aplasia at 3, 6, 9, and 12 months
are 63% (range, 51%–73%), 72% (range, 59%–82%), 83% (range,
70%–91%), and 88% (range, 73%–95%), respectively]. There
were six patients who had B-cell recovery after 1 year (from
12–37 months), five with ongoing response (follow-up 18–48
months) without further therapy, and one lost to follow-up
at month 23.

Multivariate and Combined Analysis Models
We created multivariate Cox models looking at timedependent B-cell aplasia versus BMNGS-MRD = 0 at day
28 and month 3 after infusion as risk factors for relapse. At
day 28, CR/CRi patients with BMNGS-MRD >0 had a significantly higher risk for relapse compared with those with
BMNGS-MRD = 0 (HR = 4.87; 95% CI, 2.18–10.8; P < 0.001;
Fig. 5A). B-cell recovery within the first year remained an
independent risk factor for relapse (HR = 3.33; 95% CI,
1.44–7.69; P = 0.005; Fig. 5A and B). Notably, patients with
BMNGS-MRD >0 at 3 months had extremely poor outcomes
compared with those with BMNGS-MRD = 0 (HR = 12; 95%
CI, 2.87–50; P < 0.001; Fig. 5C and D). At this point, additional B-cell recovery data did not have an independent
impact on subsequent outcomes.
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Figure 4. Univariate Cox model to assess the time-dependent effect of B-cell recovery on EFS. A, HR, confidence interval, and P value for the risk of
relapse once patients had B-cell recovery within 1 year after infusion. B, Adjusted EFS curves based on the Cox model from A for patients with B-cell
recovery by month 3 (M3), month 6 (M6), month 9 (M9), and month 12 (M12). C, Landmark EFS analysis for patients with persistent B-cell aplasia and
reaching M3, M6, M9, and M12.

Clinical Associations with CD19+ or CD19- Relapse
We sought to define possible clinical associations with
CD19+ and CD19− relapse. The timing of CD19+ versus
CD19− relapse largely overlaps, occurring both early and
late, with the large majority of relapses occurring within
the first year after infusion (Fig. 6A). Notably, B-cell recovery did not have an impact on the timing of CD19+ and
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CD19− relapse (Fig. 6B), with a possible exception of a delay
in CD19+ relapses in a few patients with persistence of
B-cell aplasia (purple line in Fig. 6B). An important result
of this analysis, however, is that we show that CD19− relapse
occurs in the setting of persistent B-cell aplasia (Fig. 6C).
Twenty-two of the 25 CD19− relapses occurred in the presence of B-cell aplasia, whereas 11 of the 14 CD19+ relapses
occurred after loss of B-cell aplasia. Notably, two of the three
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Figure 5. Multivariate Cox proportional hazards analyses for EFS combining BMNGS-MRD status (fixed times at day 28 or month 3) and B-cell

recovery (time-dependent covariate). A, Results from multivariate Cox model for EFS using day 28 BMNGS-MRD status and B-cell recovery data within
the first year (n = 66). B, Adjusted EFS curves based on the Cox model in A. C, Results from multivariate Cox model for EFS using month 3 BMNGS-MRD
status and B-cell recovery data within the first year (n = 45). D, Adjusted EFS curves based on the Cox model in C.

CD19+ relapses in the context of B-cell aplasia were isolated
extramedullary relapses, and the third relapse was CD19dim.
We previously observed that patients experiencing CD19+
relapse had lower CAR-T cell expansion and earlier loss of
persistence in contrast to patients with CD19− relapse (17).
We further hypothesized that differing CAR-T cell kinetic
profiles might exist between CD19+ and CD19− relapses.
Figure 6D and E show an analysis of whether the area under
the curve (AUC0–28d, CAR-T cell exposure during the first 28

days after infusion) and maximal (peak) of expansion kinetics (Cmax) as measured by transgene levels had an effect on
CD19− or CD19+ relapse frequency. Notably, patients with
CD19+ relapse had significantly lower AUC0–28d and Cmax
compared with patients with CD19− relapse. Consistent with
this finding, there was significantly more grade 3/4 cytokine
release syndrome (CRS) in patients with CD19− relapse (64%,
16/25) compared with those with CD19+ relapse (22%, 3/14;
P = 0.02). Higher CAR-T cell expansion in patients leads to
JANUARY 2022
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Figure 6. Comparison of time to relapse, B-cell recovery incidence, and tisagenlecleucel expansion in CD19− and CD19+ relapse patients. A, Kaplan–
Meier (KM) analysis for time to relapse by CD19 status: CD19- (red) and CD19+ (aqua). B, KM analysis for cumulative incidence of relapse by B-cell
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higher grades of CRS (18). In addition. patients with higher
disease burden and higher CAR-T cell expansion who have
persistent B-cell aplasia are more likely to have CD19− relapse
if relapse occurs. Although tumor burden at enrollment was
not different between CD19− (15 high and 10 low) and CD19+
(11 high and 3 low) relapse patients (P = 0.31), these studies
did not measure tumor burden at the time of lymphodepleting chemotherapy or just prior to CAR-T cell infusion.

DISCUSSION
In this analysis of combined ELIANA/ENSIGN data, we
noted that the large majority (82%) of relapses after tisagenlecleucel occur within the first year after infusion. Given
that half of patients treated with tisagenlecleucel have the
potential for long-term response/possible cure without HCT,
biomarkers defining relapse risk within the first year after
infusion could have a major impact, identifying patients for
whom HCT or other relapse prevention therapies, including reinfusion, could be considered. We looked at multiple
disease, treatment, and demographic characteristics to define
appropriate markers and found no effect of age, cytogenic or
genetic risk (Supplementary Fig. S4), sex, or prior therapy.
While we did observe lower EFS/OS in univariate analysis of
patients with high tumor burden at enrollment, the studies
did not quantitate tumor burden at time of CAR-T cell infusion, a time point that is likely more clinically meaningful. In
addition, tisagenlecleucel was able to induce deep remissions
(NGS-MRD = 0) equally well in patients with high or low
tumor burdens. Of all the clinical and biological characteristics we analyzed, the most important and actionable risk factors for long-term outcomes were persistence of B-cell aplasia
and detection of NGS-MRD.
In practice, B-cell aplasia has been used as a pharmacodynamic indicator of CAR-T functional persistence (5). This
was confirmed by our univariate Cox analysis using B-cell
recovery as a time-dependent covariate, showing a significant
association between B-cell recovery and shorter EFS. However, measuring B-cell aplasia after CAR-T cell treatment by
itself is not sufficient to predict relapse, as CD19− relapse
can occur early and at higher frequency in patients with
persistence of B-cell aplasia (Fig. 6B and C). Notably, late
loss of B-cell aplasia (12 months after CAR-T cell infusion)
may have less of a prognostic impact (five of six patients
with B-cell recovery after 1 year had ongoing response). Loss
of B-cell aplasia varies over time, with the large majority of
patients who are going to lose B-cell aplasia doing so prior to
6 months (20 of 31 or 65% of patients with B-cell recovery).
After this time point, patients lose B-cell aplasia at a slow rate
over subsequent years. Our analysis of loss of B-cell aplasia
as a time-dependent variable over the first year after therapy
showed a clear decrease in the prognostic importance of the
persistence of B-cell aplasia over time. Although we have sufficient numbers to state that loss of B-cell aplasia in the first 6
months leads to poor outcomes, better understanding of the
prognostic significance of “late” loss of B-cell aplasia (6–12
months or >1 year after infusion) will require larger patient
numbers because it occurs less often.
Measurements of MRD by MFC or PCR are well established in ALL and have been used along with other clinical

RESEARCH ARTICLE
parameters to guide intensity of therapy (11, 19–21). Presence
of pre- and post-HCT MRD guides approaches to HCT and
withdrawal of immune suppression (12, 22–24). NGS-MRD
testing markedly increases the level of sensitivity in detecting leukemia in the marrow, and this test has been shown to
define patients at low risk of relapse when treated with both
chemotherapy and HCT (14, 15). In a recent report of pediatric patients with B-cell ALL treated with tisagenlecleucel, the
absence of complete MRD response (PCR with ≥10−4 sensitivity level), B-cell aplasia, and incidence of CRS was associated
with increased cumulative incidence of relapse (25). In this
study, we found that MFC-MRD measurements from marrow after CAR-T cell infusion were of limited benefit in spite
of having a very high positive predictive value. MFC assessment detected disease quite late; if relapse had not occurred
already, there was limited time to plan and initiate therapy to
prevent relapse, and outcomes were poor.
Our data show that BMNGS-MRD measurements are the
most sensitive biomarker to date for defining risk of relapse
after CAR-T cell therapy. It is notable that using LOD and
LOQ cutoffs for sensitivity as low as 10−6 with the commercially available NGS-MRD assay (Adaptive Biotechnologies),
we did not observe the prognostic importance of BMNGSMRD at day 28 after therapy until we considered any level of
detection of NGS-MRD to be high risk. This is likely because
CAR-T cells routinely put patients into very deep remissions,
but at the same time, any detectable disease at any level using
these assays is an indication that the CAR-T cell response
may not be sufficient for long-term disease control. At day
28 after infusion, there is a small percentage of patients who
have BMNGS-MRD detectable disease who go on to have
long-term responses. This may indicate that, in a fraction of
patients, the response is not complete at day 28 and may be
continuing. Repeat BMNGS-MRD after the initial positive
result may help better define risk in patients with low levels
of positivity at day 28. Of note, however, by 3 months and at
all later time points that we measured up to month 12, any
detectable disease by BMNGS-MRD was highly prognostic,
and 41 of 42 patients with measurable disease at these later
time points in our study either relapsed or were censored for
HCT or other therapies.
When measuring NGS-MRD, it is important to understand definitions of LOD/LOQ and the limitations of the
assay. The LOD is defined as the malignant cell count at
which the assay would detect MRD in 95% of samples.
The LOQ is defined as the lowest sample MRD frequency
that could be quantitatively determined within 70% relative total error (26). In general, detection of unique clones
clearly associated with the patient’s blasts is highly specific.
When patients have disease detectable under the LOD
and LOQ cutoffs, there is a chance that a second BM test
from the same patient may not have detected the disease.
Because LOD and LOQ are proportional to the number
of cells assayed, a simple way to improve our ability to
detect disease in this setting would be to be generous with
the number of cells sent from BM aspirates (if possible,
preferably >107 total cells). These limitations also reinforce
the value of repeat testing, and underline that optimal frequency and timing of testing after CAR-T cell therapy are
not known.
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In this study, we also showed that a combination of assessing B-cell aplasia along with BMNGS-MRD measures is
important. Patients who lose B-cell aplasia early do poorly.
The strongest effect on risk of relapse occurs with B-cell
recovery within the first 6 months, and the effect decreases
by 12 months (Fig. 4B). Although day 28 measures of NGSMRD = 0 and B-cell aplasia are independently predictive
of good outcomes, by 3 months, NGS-MRD >0 is a powerful predictor of relapse. Although positive BMNGS-MRD
predicted relapse in our patients very accurately, negative
BMNGS-MRD at a single time point is not sufficient to
ensure patients will not relapse, and they should continue to
be monitored at intervals over time.
With these data in hand, who should undergo HCT after
tisagenlecleucel? It is clear that any patient who loses B-cell
aplasia prior to 6 months and who does not have an alternative approach (humanized CAR-T cells, experimental CAR-T
cell reinfusions, etc.) has a high probability of relapse. HCT
prior to relapse is very reasonable for those eligible for HCT
in this population, especially if they have not had a previous
HCT. A second group of patients for consideration of HCT
or experimental approaches would be those with detectable
BMNGS-MRD disease. Those with BMNGS-MRD >0 at 1
month may benefit from a confirmation 2 to 4 weeks later,
but those with later measures of BMNGS-MRD >0 may not
require confirmation. A population that may or may not
benefit from HCT after CAR-T cells is patients who have not
had HCT and who fall into a “low-risk” category (they have
B-cell aplasia and are BMNGS-MRD = 0). Figure 3C shows
that low-risk patients still can relapse [EFS 68% (range,
54%–86%) at 2 years and 64% (range, 48%–83%) at 3 years)].
First HCT in patients with BMNGS-MRD–negative status
who are eligible for HCT results in EFS >80% (14). At the
same time, sending all such patients to HCT will include
patients already destined to do well, for whom the risks of
HCT may be unwarranted. Whether these lower risk patients
would benefit from HCT requires further study, likely a randomized comparison.
A final intriguing outcome is our observation that continued B-cell aplasia is highly associated with CD19− relapse.
Although this aligns with the mechanism of tisagenlecleucel,
the additional observations we make (higher AUC0–28d/Cmax
and grade 3/4 CRS are also highly associated with CD19−
relapse) provide supporting evidence that selective pressure
of CAR-T cells, especially where there is higher disease bur
den, by itself may be important in determining whether
patients will have a CD19− relapse. Some investigators have
suggested that CD19− relapse could be driven by patients
coming to CAR-T cell treatment with very low levels of CD19−
mutations present (27). Our cohort included flow assessment
that looked for CD19− clones prior to treatment, and no
enrolled patients had clearly defined CD19− clones; however,
this method may not be sufficient to detect very low-level
CD19− clones. Further study of this population, including
detailed molecular studies of CD19 mutational status at
baseline along with timing and molecular characterization
of CD19− relapses, is underway and will be reported separately. CAR-T cell expansion and high-grade CRS are highly
associated with disease burden at time of infusion (6) but
may also point to selection pressure from high early CAR-T
78 | BLOOD CANCER DISCOVERY
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cell expansion and continuous late exposure as being key
to CD19− relapse. Alternatively, higher disease burden may
allow for a higher number of CD19− clones that may give rise
to a CD19− relapse (6).
This study has important limitations. Although we had
nearly 1,800 MFC-MRD measurements, we had just under
500 NGS-MRD assessments. A high percentage of patients
had marrow checked at 1 and 3 months, but more limited
numbers of patients had samples at 2, 4, or 6 months—
times that may also inform clinical decision-making. We
also do not have a sufficient number of peripheral blood
NGS-MRD samples to adequately define a role for assessing relapse risk by this much more accessible approach. In
short, larger numbers, assessment of more time points after
CAR-T cell infusion, and comparison of peripheral blood
NGS-MRD measurements with BMNGS-MRD measurements will be needed to further refine the use of NGS-MRD
as a biomarker to predict relapse. Notably, clonality analyses
comparing MRD clones with their corresponding baseline
ID clones showed all patients kept the same identifying
IgH rearrangements as baseline, with no loss of identifying
clonal sequences, regardless of CD19 status. Two patients
with MLL rearrangement who relapsed with lineage switch
also retained their identifying clonal IgH gene rearrangements, confirming that the lineage-switched clones emerged
from the previous leukemia.
In conclusion, this study demonstrates that the best biomarker described to date for determining risk of relapse at
any given time throughout the first year after CAR-T cell
therapy with tisagenlecleucel is NGS-MRD assessment of the
marrow with a cutoff of >0 cells detected. B-cell aplasia during the first year is also a strong biomarker, defining patients
with possible long-term response. Those who lose B-cell
aplasia prior to 6 months or develop NGS-MRD measures >0
on marrow examination are at high risk of relapse, and HCT
or other cell or immune therapies should be considered.
Whether low-risk patients who have undetectable BMNGSMRD early on who have not undergone HCT could benefit
from early HCT after CAR-T cell therapy is not known and
requires further study. How peripheral blood monitoring of
NGS-MRD could fit into management of CAR-T cell patients
also requires further study.

METHODS
Patient Populations
Two phase II, single-arm, multicenter global studies [ELIANA,
N = 79 (NCT02435849), data cutoff date July 1, 2019; ENSIGN,
N = 64 (NCT02228096), data cutoff date May 24, 2019] were
conducted including 143 pediatric and young adult patients
with CD19+ relapsed or refractory B-cell ALL who were infused
with tisagenlecleucel (1). Study protocols were implemented and
reported with the ethical principles laid down in the Declaration
of Helsinki, and were approved by individual Institutional Review
Boards; written informed consents were obtained for all patients.
To be eligible for participation in the studies, patients had to be
3 years of age at screening and no older than 21 years of age at
diagnosis and have >5% lymphoblasts detected by morphology
in BM at screening. Patients who had previously received antiCD19 therapy were excluded. Eligibility criteria of the two protocols were overlapping with minimal differences (Supplementary
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Table S2). CAR-T cells for the first 29 patients in the ENSIGN trial
were manufactured by the University of Pennsylvania GMP facility, and the CAR-T cells for the remaining 35 on ENSIGN and all
79 ELIANA patients were manufactured at Novartis. Lymphodepleting chemotherapy was used in 136 of 143 patients before a
single infusion of 0.2 to 5 × 106/kg (patients ≤50 kg) or 0.1 to
2.5 × 108 (patients >50 kg) tisagenlecleucel.

MRD Detection by Flow Cytometry
MFC-MRD was measured on fresh blood and BM samples by a
central laboratory using a three-tube, eight-color flow cytometry assay
with a lower limit of sensitivity of 0.01% of viable white blood cells
(WBC). Samples were collected at screening, month 1, month 3, month
6, month 9, and month 12 after infusion. In addition, blood samples
were collected weekly during the first month, and at month 1, month
3, month 6, month 9, and month 12. After red blood cell lysis, cells
were washed and centrifuged to create a WBC pellet, which was resuspended in wash buffer (PBS + 2% FBS) and aliquoted into flow tubes.
Human Fc Receptor Binding Inhibitor (Thermo Fisher Scientific) was
added to each tube to reduce nonspecific binding. The suspension was
stained with a preprepared qualified antibody cocktail including CD9
(clone M-L13, BD), CD10 (clone HI10a, BD), CD13 (clone WM15,
BD), CD19 (clone SJ25C1, BD), CD20 (clone 2H7, BioLegend), CD22
(clone S-HCL-1, BD), CD33 (clone P67.6, BD), CD34 (clone 8G12,
BD), CD38 (clone HB7, BD), CD45 (clone HI30, BD), CD58 (clone
IC3, BD), CD66c (clone B6.2/CD66, BD), and CD123 (clone 9F5, BD).
After incubation, samples were washed, fixed in 0.5% formalin buffer,
and acquired on a FACSCanto II cytometer (BD). Data analyses were
performed using FCS Express software (De Novo Software).
BM and blood MRD positivity was defined as ≥0.01% leukemic
cells out of total viable WBCs. B-cell recovery was defined as the time
from onset of remission to the earliest time when blood CD19+ total
B cells ≥1% among viable WBCs or ≥3% among lymphocytes.

Ig NGS-MRD Assay
NGS-MRD was measured using ClonoSEQ B-cell Clonality (Adaptive Biotechnologies), an NGS-based assay designed for tumorspecific Ig sequence rearrangement detection. It identifies and tracks
rearranged IgH (VDJ), IgH (DJ), IgK, and IgL receptor gene sequences,
as well as translocated BCL1/IgH (J) and BCL2/IgH (J) sequences. A
subset of BM and blood samples were collected at screening, end of
month 1, every 3 months during the first year, and every 6 months
during the second year after infusion. Of 117 baseline samples that
passed quality control, 111 (95%) had index clones identified. For
patients with baseline ID sequences identified, MRD results were
reported in postinfusion samples both quantitatively (number of
malignant cells per million nucleated cells) and qualitatively (positive or negative at the sensitivity thresholds of 10−4, 10−5, and 10−6,
or indeterminate for MRD− samples with insufficient numbers of
assayed cells). In addition, detectable MRD (MRD >0) was defined
as any level of MRD regardless of LOD cutoffs to capture those with
disease burden below 10−6 but higher than 0.

Detection of Tisagenlecleucel Transgene
Detection of tisagenlecleucel transgene DNA and calculation of
cellular kinetic parameters [AUC0–28d: expansion and persistence of
tisagenlecleucel during the first 28 days; Cmax: the maximum (peak)
expansion of tisagenlecleucel] from peripheral blood samples were
described previously (15).

Definition of Relapse
Morphologic relapse was defined as blasts in the blood (≥1%),
blasts in BM (≥5%), or any extramedullary disease after CR or CRi.
Patients who became MRD+ (≥0.01% leukemic cells) after remission

RESEARCH ARTICLE
were defined as MFC-MRD+ CD19 status at relapse was derived
from flow MRD result when a patient first turned MRD+. Time to
relapse is defined as the earlier time of morphologic relapse and/or
MFC-MRD+ when correlated with CD19 status.

Statistical Analysis
All statistical analyses were performed using RStudio (RStudio
Team 2019. RStudio: Integrated Development for R. RStudio, Inc.;
http://www.rstudio.com/). EFS was the time from tisagenlecleucel
infusion to the earliest of death, relapse, or treatment failure. EFS
analyses were performed in ongoing responding patients at the
end of day 28, month 3, or month 6, with relapse being the only
event. EFS was censored at last assessment date for patients without events, lost to follow-up, undergoing new cancer therapy, or
undergoing HCT. Kaplan–Meier curves were used to compare EFS
and OS in responding patients with known NGS Ig MRD status at
landmark times of 1, 3, and 6 months after infusion, and P values
within BMNGS-MRD subgroups (detectable vs. nondetectable) were
calculated using the log-rank test.
A univariate Cox model for EFS analysis was developed using B-cell
recovery as a time-dependent covariate to assess the effect of B-cell recovery on relapse starting from the day a patient achieved B-cell recovery. All
blood longitudinal B-cell measurements after remission within the first
year were included, and categorized as recovery and no recovery based
on the criteria mentioned above. Patients who had B-cell recovery at the
same day as relapse were treated as no B-cell recovery. Similarly, multivariate Cox models combining day 28 and month 3 BMNGS-MRD
status and time-dependent B-cell recovery data were explored. Only
patients with EFS longer than 1 month or 3 months were included in
these multivariate Cox models.
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